FLOW CYTOMETRIC EVALUATION OF MDS/AML

被引：0
|
作者：
Kern, Wolfgang [1 ]
机构：
[1] MLL Munich Leukemia Lab, Munich, Germany
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2014年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [41] Connect MDS and AML: The myelodysplastie syndromes (MDS) and acute myeloid leukemia (AML) disease registry.
    Steensma, David P.
    Abedi, Mehrdad
    Attar, Eyal C.
    Bejar, Rafael
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Ma, Xlaomei
    Maciejowski, Jaroslaw P.
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael
    Scott, Bart L.
    Sekenos, Mikkael A.
    Thompson, Michael A.
    Zernovak, Oleg
    Sugrue, Mary M.
    Swern, Arlene S.
    Nifonecker, Melissa
    Erba, Harry Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
    Ohm, AC
    Hast, R
    Bernell, P
    Celsing, F
    Dahl, IM
    Dybedal, I
    Lindberg, G
    Linder, O
    Löfvenberg, E
    Nilsson-Ehle, H
    Samuelsson, J
    Tangen, J
    Turesson, I
    Wallvik, J
    Winquist, I
    Öberg, G
    Björkholm, M
    Hellström-Lindberg, E
    BLOOD, 2000, 96 (11) : 148A - 148A
  • [43] FlowSOM, an unsupervised clustering method, improves flow cytometric MRD detection in AML patients
    Anastasiou, M.
    Bounaix, L.
    Dufour, A.
    Green, A.
    Lacombe, F.
    Matthes, T.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [44] Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiative
    Buecklein, V
    Schnorfeil, F.
    Koehnke, T.
    Spiekermann, K.
    Krause, S. W.
    Oelschlaegel, U.
    Voelkl, S.
    Rieger, M. A.
    Berg, T.
    Hoffmann, J.
    Brendel, C.
    Hofmeister-Mielke, N.
    Kriegsmann, K.
    Thiede, C.
    von Bonin, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 80 - 80
  • [45] Azacitidine Treatment of MDS/AML: Effect on Immunophenotyping by Flow Cytometry and Associated Cytogenetic Findings
    Torabi, A.
    Huang, J. Z.
    Douglas-Nikitin, V. K.
    Smith, M. D.
    LABORATORY INVESTIGATION, 2011, 91 : 326A - 326A
  • [46] Azacitidine Treatment of MDS/AML: Effect on Immunophenotyping by Flow Cytometry and Associated Cytogenetic Findings
    Torabi, A.
    Huang, J. Z.
    Douglas-Nikitin, V. K.
    Smith, M. D.
    MODERN PATHOLOGY, 2011, 24 : 326A - 326A
  • [47] SNP/CGH MICROARRAY ANALYSIS IN MDS: CORRELATION WITH CONVENTIONAL CYTOGENETICS, FISH AND FLOW CYTOMETRIC FINDINGS
    Zehentner, B.
    Broderson, L.
    Stephenson, C.
    Cutler, J.
    de Baca, M.
    Menssen, A.
    Hammock, K.
    Johnson, K.
    Hartmann, L.
    Loken, M.
    Wells, D.
    LEUKEMIA RESEARCH, 2015, 39 : S86 - S86
  • [48] Animal models for AML, MDS and MPN
    Kitamura, Toshio
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 197 - 197
  • [49] Categorizing Molecular Mutations in MDS and AML
    Rose, Dominic
    Haferlach, Torsten
    Kern, Wolfgang
    Haferlach, Claudia
    BLOOD, 2015, 126 (23)
  • [50] What came first: MDS or AML?
    Walter, Matthew J.
    BLOOD, 2015, 125 (09) : 1357 - 1358
12345